

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)

LURASIDONE FOR SCHIZOPHRENIA

RECOMMENDED FOR RESTRICTED USE (AMBER INITIATION)

Name: generic (trade)	What it is	Indication	Date decision last revised	Decision status	NICE / SMC Guidance
Lurasidone (Latuda ®)	Second-generation (atypical) antipsychotic	Licensed for the treatment of schizophrenia in adults and adolescent aged 13 years and over	September 2022	Final	SMC: accepted for restricted use AWMSG: recommended as an option for treatment of schizophrenia

HWE APC recommendation:

Lurasidone is recommended with an Amber Initiation status for use within its licensed indication (i.e. for schizophrenia) for adult patients (aged 18 years and over) once aripiprazole has either failed to manage the patient's condition or is not suitable due to a contraindication or intolerance. Initiation, clinical stabilisation (assessment of efficacy and side effects) and dose stabilisation to be carried out by specialist (usually at least 3 months), with continuation in primary care.